-
公开(公告)号：US11254740B2
公开(公告)日：2022-02-22
申请号：US16435960
申请日：2019-06-10
Applicant: Bristol-Myers Squibb Company
Inventor： Brenda L. Stevens , Mark W. Rixon , Scott R. Presnell
IPC: A61K39/395 , C07K16/24 , C07K16/46 , A61K39/00
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
公开(公告)号：US20170022272A1
公开(公告)日：2017-01-26
申请号：US15289463
申请日：2016-10-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L STEVENS , Mark W. Rixon , Scott R. Presnell
IPC: C07K16/24
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
公开(公告)号：US20150099278A1
公开(公告)日：2015-04-09
申请号：US14576278
申请日：2014-12-19
Applicant: Bristol-Myers Squibb Company
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: C07K16/24
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
公开(公告)号：US10358490B2
公开(公告)日：2019-07-23
申请号：US15694374
申请日：2017-09-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: A61K39/395 , C07K16/24 , C07K16/46 , A61K39/00
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
公开(公告)号：US09708401B2
公开(公告)日：2017-07-18
申请号：US14402322
申请日：2013-05-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Mark W. Rixon , Scott R. Presnell
IPC: A61K39/395 , C07K16/24 , C07K16/46 , A61K39/00
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
Patent Agency Ranking
公开(公告)号：US08945553B2
公开(公告)日：2015-02-03
申请号：US13898544
申请日：2013-05-21
Applicant: Bristol-Myers Squibb Company
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: A61K39/395 , C07K16/46 , C07K16/24 , A61K39/00
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
公开(公告)号：US20200040072A1
公开(公告)日：2020-02-06
申请号：US16435960
申请日：2019-06-10
Applicant: Bristol-Myers Squibb Company
Inventor： Brenda L. Stevens , Mark W. Rixon , Scott R. Presnell
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
公开(公告)号：US20180037645A1
公开(公告)日：2018-02-08
申请号：US15694374
申请日：2017-09-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
公开(公告)号：US20170275357A1
公开(公告)日：2017-09-28
申请号：US15620358
申请日：2017-06-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Mark W. Rixon , Scott R. Presnell
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
公开(公告)号：US20150086552A1
公开(公告)日：2015-03-26
申请号：US14402322
申请日：2013-05-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty , Milan Gao , Steven Sheriff , Noah Ditto , Nels B. Hamacher
IPC: C07K16/24
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.034 seconds)
